Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Evocutis
Evocutis
Activities:
Regulatory
Research & Development
Skin Care
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Skin Care
Venn Life Sciences acquires trading assets of Evocutis
Including intellectual property rights to Labskin and anti-acne compound SYN1113
Regulatory
Evocutis and Bradford University Collaborate on pigmented LabSkin
Aim to discover improved ways of investigating common pigment-related skin conditions
Regulatory
Evocutis secures first contracts for LabSkin living skin equivalent
Offers an alternative to ethically sensitive and expensive animal and human volunteer testing
Research & Development
Evocutis joins European platform to promote alternatives to animal testing
After making presentation about its LabSkin technology
Ingredients
Syntopix develops microemulsions for healthcare and cosmetic products
Identifies two green surfactants for oral care
Manufacturing
Syntopix plans to buy Leeds Skin
Key attraction of acquisition is Leeds Skin’s LabSkin technology
Ingredients
Syntopix to develop new microemulsions
Wins support from Intelligent Formulation
Subscribe now